Nyxoah SA NYXH
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Nyxoah SA (NYXH) is a healthcare company listed in the US with a market value of about $90M. In fiscal year 2025 it had revenue of $12M and net income of -$106M, a net margin of -899.1%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 168% a year, a 5-year average ROIC of -51%.
About Nyxoah SA
Nyxoah SA is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $84670 in 2020 to $12M in 2025, growth of about 168.3% a year. It was profitable in 0 of the last 6 years in our data.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $12M | $5M | $5M | $3M | $964980 | $84670 |
| Net income | -$106M | -$62M | -$48M | -$33M | -$31M | -$15M |
| Free cash flow | -$82M | -$52M | -$52M | -$32M | -$30M | -$9M |
| EPS (diluted) | $-1.06 | $-0.61 | $-0.48 | $-0.33 | $-0.31 | $-0.15 |
| Net margin | -899.1% | -1310.2% | -993.8% | -1012.5% | -3241.7% | -17746.4% |
| ROIC | -134.2% | -41.0% | -44.5% | -21.3% | -14.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Nyxoah SA pay a dividend?
Not currently.
Is Nyxoah SA a good stock to buy?
We do not give buy or sell advice. Nyxoah SA scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.